Pulmatrix Q4 revenue down 45%, focuses on licensing and monetizing assets.

• Pulmatrix plans to license or monetize migraine and inhalation assets • Focused on advancing steps to complete merger with Cullgen • Pulmatrix's iSPERSE™ technology is used to prevent and treat migraine and respiratory diseases • Merger with Cullgen is focused on protein degrader therapies for pain, cancer, and other diseases • Pulmatrix's 2025 year-end and Q4 financial results are available • Company continues to work with Cullgen for CSRC approval in China • Pulmatrix's iSPERSE™ technology has potential for unmet medical needs in respiratory diseases • Pulmatrix's merger with Cullgen aims to address unmet medical needs in pain, cancer, and other diseases • Pulmatrix's technology has potential for treatment of migraine and respiratory diseases • Pulmatrix's merger with Cullgen is focused on targeted protein degrader therapies for various diseases • Pulmatrix's iSPERSE™ technology is used to develop inhaled therapeutic products for various diseases.